Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/artrya-ltd">Artrya </a>is a medical technology company at the forefront of developing AI-driven solutions for the diagnosis of coronary artery disease (CAD), the leading cause of death globally.</li>
  <li>The company's flagship product, Salix, is a cloud-based platform that analyzes cardiac CT scans to detect and quantify arterial plaque, providing clinicians with a comprehensive report in approximately 10-15 minutes, a significant improvement over the 24-hour turnaround of existing methods.</li>
  <li>With recent regulatory approvals in key markets, including the US, Europe, and Australia, and partnerships with major healthcare providers, <a href="https://smartkarma.com/entities/artrya-ltd">Artrya </a>is poised for commercial rollout and significant revenue growth in a multi-billion dollar addressable market.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Artrya is a medical technology company at the forefront of developing AI-driven solutions for the diagnosis of coronary artery disease (CAD), the leading cause of death globally.
  The company's flagship product, Salix, is a cloud-based platform that analyzes cardiac CT scans to detect and quantify arterial plaque, providing clinicians with a comprehensive report in approximately 10-15 minutes, a significant improvement over the 24-hour turnaround of existing methods.
  With recent regulatory approvals in key markets, including the US, Europe, and Australia, and partnerships with major healthcare providers, Artrya is poised for commercial rollout and significant revenue growth in a multi-billion dollar addressable market.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

<ul>
<li>Extra Edition of the Broker Call Report</li>
</ul>


Extra Edition of the Broker Call Report


Artrya Ltd - Australian Broker Call *Extra* Edition - Jun 18, 2025

Australia

Artrya Limited operates as an artificial intelligence healthcare company. The Company works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient. Artrya serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Artrya (AYA AU)

Primer: Artrya (AYA AU) - Dec 2025

Artrya is a medical technology company at the forefront of developing AI-driven solutions for the diagnosis of coronary artery disease (CAD),...

αSK

Artrya Ltd - Australian Broker Call Extra Edition - Jun 18, 2025

Extra Edition of the Broker Call Report

FNArena

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)